跳至主要内容
临床试验/NCT01738373
NCT01738373已完成不适用

Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study

Genzyme, a Sanofi Company0 个研究点目标入组 262 人开始时间: 2011年12月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
262
主要终点
Duration of treatment

研究概览

简要总结

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients treated with Plerixafor for autologous transplantation between November 2011 and November 2012
  • Patients who have been informed and who have given their written consent for the access to their medical file

排除标准

  • Patients already included in a Plerixafor ongoing clinical trial.

结局指标

主要结局

Duration of treatment

时间窗: 13 months

Associated treatments

时间窗: 13 months

The characteristics of the patients who received treatment

时间窗: 13 months

Dosage of treatment

时间窗: 13 months

Number of CD34+ cells collected following treatment

时间窗: 13 months

Number of patients with the existence of one or more predictive factors of poor mobilisation

时间窗: 13 months

次要结局

未报告次要终点

研究者

发起方
Genzyme, a Sanofi Company
申办方类型
Industry
责任方
Sponsor

相似试验

Registry of Patients Treated With Plerixafor... | 临床试验